Year All2024202320222021202020192018201720162015 Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema October 24, 2024 Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 17, 2024 Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 October 3, 2024 Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients September 27, 2024 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma September 16, 2024 Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting September 5, 2024 Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma September 4, 2024 Poseida Therapeutics to Present at Upcoming Investor Conferences August 29, 2024 Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 August 5, 2024 Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum July 1, 2024
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema October 24, 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 17, 2024
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 October 3, 2024
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients September 27, 2024
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma September 16, 2024
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting September 5, 2024
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma September 4, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 August 5, 2024
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum July 1, 2024